Antibody drug conjugate (ADC) biotech Mersana Therapeutics Inc. has thrown out its lead candidate XMT-1522. The ADC, partnered with Takeda Pharmaceutical Co. Ltd., targeted HER2-expressing tumors and was built using Mersana’s proprietary Dolaflexin platform.
Such was Takeda’s early confidence in the ADC that it paid $40m up front in 2016 and agreed to pay another $20m once an IND was accepted by the FDA. Mersana retained all US and Canadian rights to the drug, with Takeda taking responsibility for rest-of-world commercialization. (Also see "Mersana/Takeda Deal Adds To ADC Pipeline" - Scrip, 3 February, 2016
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?